<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632331</url>
  </required_header>
  <id_info>
    <org_study_id>8825-CL-0014</org_study_id>
    <nct_id>NCT02632331</nct_id>
  </id_info>
  <brief_title>ASP8825 - A Study to Investigate the Food Effect on the Pharmacokinetics of ASP8825</brief_title>
  <official_title>Pharmacokinetic (PK) Study of ASP8825 - Evaluation of the Effect of Food on the Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effect of food on the pharmacokinetics and
      safety after administration of ASP8825 in healthy non-elderly adult male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter of gabapentin: Cmax</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hr after dosing</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters of gabapentin: AUClast</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hr after dosing</time_frame>
    <description>AUClast: Area under the concentration-time curve from the time of dosing extrapolated to the last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by AEs</measure>
    <time_frame>Up to 8 days after the final study drug dosing</time_frame>
    <description>AEs: Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Vital signs</measure>
    <time_frame>Up to 3 days after the each study drug dosing</time_frame>
    <description>Supine blood pressure, supine pulse rate and axillary body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by Laboratory tests</measure>
    <time_frame>Up to 3 days after the each study drug dosing</time_frame>
    <description>Hematology, blood biochemistry, and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by 12-lead ECGs</measure>
    <time_frame>Up to 3 days after the each study drug dosing</time_frame>
    <description>ECG: Electrocardiogram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of gabapentin tmax</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hr after dosing</time_frame>
    <description>tmax: Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of gabapentin: AUCinf</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hr after dosing</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of gabapentin: t1/2</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hr after dosing</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of gabapentin: CL/F</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hr after dosing</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of gabapentin: MRTinf</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hr after dosing</time_frame>
    <description>MRTinf: Mean residence time from the time of dosing extrapolated to time infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of gabapentin: MRTlast</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hr after dosing</time_frame>
    <description>MRTlast: Mean residence time from the time of dosing extrapolated to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of gabapentin: kel</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hr after dosing</time_frame>
    <description>kel: Terminal elimination rate constant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Fasted dosing preceding group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fed dosing preceding group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP8825</intervention_name>
    <description>Oral</description>
    <arm_group_label>Fasted dosing preceding group</arm_group_label>
    <arm_group_label>Fed dosing preceding group</arm_group_label>
    <other_name>gabapentin enacarbil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight: ≥50.0 kg and &lt;80.0 kg

          -  Body mass index BMI: ≥17.6 and &lt;26.4 [BMI= Body weight (kg)/(Height (m))2]

        Exclusion Criteria:

          -  Subjects who received any study drugs in other clinical trials or post-marketing
             studies within 120 days before screening

          -  Subjects who received or are scheduled to receive medications (including
             over-the-counter [OTC] drugs) within seven days before the hospital admission day of
             period 1.

          -  Subjects who deviate from the normal range of blood pressure, pulse rate, body
             temperature and standard 12-lead ECG at screening or the hospital admission day of
             period 1

          -  Subjects who meet any of the criteria for laboratory tests at screening or the
             hospital admission day of period 1. Normal ranges of each test specified at the study
             site or the test/assay organization will be used as the normal ranges in this study.

          -  Subjects with a complication of drug allergies

          -  Subjects who developed upper gastrointestinal symptoms (e.g., nausea, vomiting, and
             stomachache) within seven days before the hospital admission day of period 1

          -  Subjects with a complication or history of hepatic disease (hepatitis viral and
             drug-induced liver injury, etc.)

          -  Subjects with a complication or history of heart disease (cardiac failure congestive,
             angina pectoris and arrhythmia requiring treatments, etc.)

          -  Subjects with a complication or history of respiratory disease (severe asthma
             bronchial and bronchitis chronic, etc.) (except for a history of non-severe infantile
             asthma)

          -  Subjects with a complication or history of alimentary disease (severe peptic ulcer,
             reflux esophagitis, etc.) (except for a history of appendicitis)

          -  Subjects with a complication or history of renal disease (acute kidney injury,
             glomerulonephritis, nephritis interstitial, etc.) (except for a history of calculus)

          -  Subjects with a complication or history of cerebrovascular disorder (cerebral
             infarction, etc.)

          -  Subjects with a complication or history of malignant tumor

          -  Subjects who have a habit of excessive alcohol drinking or smoking

          -  Subjects who previously received administration of ASP8825
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Food effect</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>ASP8825</keyword>
  <keyword>XP13512</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

